50
Participants
Start Date
April 28, 2016
Primary Completion Date
October 11, 2019
Study Completion Date
October 11, 2019
Safety and efficacy assessments
Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
Mount Sinai Medical Center, New York
National Cancer Institute, Bethesda
Sarah Cannon Research Institute, Nashville
Mayo Clinic Cancer Center, Rochester
Stanford Cancer Center, Palo Alto
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Hackensack University Medical Center, Hackensack
Lead Sponsor
Celgene
INDUSTRY